person · Reporting owner

BISCHOFBERGER NORBERT W

Disclosed activity across 4 companies

Tapewire entity: 16121
SEC CIK: 0001190273

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	EVP, R&D and CSO	February 15, 2018	February 23, 2018
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 27, 2026	May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date February 15, 2018 · Filed February 23, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,602	Ending reported balance After 2018-02-21 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2018-02-15 · Grant · Acquired 340 · Balance 12,793 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 16,468 · Balance 29,261 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Row 3 · 2018-02-21 · Grant · Acquired 6,805 · Balance 36,066 F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 4 · 2018-02-21 · Tax withholding · Disposed 7,071 · Balance 28,995 Row 5 · 2018-02-21 · Gift · Disposed 9,393 · Balance 19,602 F4: Shares gifted to family trust.
Common StockSEC Table I · non-derivative	IndirectBy Trust	2,317,800	Reported balance After 2018-02-21 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2018-02-21 · Gift · Acquired 9,393 · Balance 2,317,800 F4: Shares gifted to family trust.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.

F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.

F4: Shares gifted to family trust.

Vir Biotechnology, Inc.

Report date May 27, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,333	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 21,333 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26	Direct	16,000	Reported balance After 2026-05-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,667	Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,667 F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.

Filing footnotes · ownership attribution and instrument terms

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2: The RSUs will vest in full on May 27, 2027.

F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.

F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kronos Bio, Inc.

Report date June 20, 2025 · Filed June 20, 2025

Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-06-20 · Other · Disposed 10,802,138 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2025-06-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.78 · Expires 2030-12-09	Direct	Reported balance After 2025-06-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-20 · Disposition to issuer · Disposed 297,186 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2032-02-15	Direct	Reported balance After 2025-06-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-06-20 · Disposition to issuer · Disposed 400,000 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2033-02-14	Direct	Reported balance After 2025-06-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-06-20 · Disposition to issuer · Disposed 570,868 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2034-02-14	Direct	Reported balance After 2025-06-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-06-20 · Disposition to issuer · Disposed 699,800 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,

F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.

F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.

F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.

F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.

F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-16 · Disposition to issuer · Disposed 9,888 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The Company Stock Option ("Option") is fully vested.

F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	250,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 12 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 263,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionConvertible Promissory Note · Derivative	Not disclosed	$0.00 Strike: $16.15	$3,000,000.00	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 11 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 185,758 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries A Preferred Stock · Derivative	1,565,475	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 10 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,651,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	300,001	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 9 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 316,501 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	263,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 8 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 263,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F6 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	263,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 7 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 263,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F5 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	263,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 263,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	263,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 263,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	PurchaseCommon Stock	95,500	$19.00	$1,814,500.00	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,370,496 F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	185,758	$16.15	$2,999,991.70	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,274,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,651,576	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,089,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:29 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	316,501	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055030 · doc4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,437,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994. Read SEC document
June 18, 2020 Filed Jun 19, 2020 22:12 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $22.96	$0.00	Disclosure SEC source: 0001209191-20-038042 · doc4.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option will vest in full on June 18, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
February 21, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	9,393	$0.00	$0.00	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,317,800 F4 · shares: Shares gifted to family trust. Read SEC document
February 21, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	9,393	$0.00	$0.00	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,602 F4 · shares: Shares gifted to family trust. Read SEC document
February 21, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	7,071	$80.69	$570,558.99	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,995 Read SEC document
February 21, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	6,805	$0.00	$0.00	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,066 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document
February 21, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	16,468	$0.00	$0.00	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,261 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Read SEC document
February 15, 2018 Filed Feb 23, 2018 23:58 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	340	$62.35	$21,198.15	Disclosure SEC source: 0001127602-18-008140 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document
February 01, 2018 Filed Feb 6, 2018 02:01 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	94,360	$0.00 Strike: $83.49	$0.00	Disclosure SEC source: 0001127602-18-004173 · form4.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,360 Underlying: Common Stock · 94,360 shares Expires 2028-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
November 20, 2017 Filed Nov 22, 2017 00:04 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-17-033091 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,308,407 F1 · shares: Gift of shares from family trust to charity. Read SEC document
February 16, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	11,558	$0.00	$0.00	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,318,407 F4 · shares: Shares gifted to family trust. Read SEC document
February 16, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	11,558	$0.00	$0.00	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,453 F4 · shares: Shares gifted to family trust. Read SEC document
February 16, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	7,070	$70.31	$497,091.70	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,011 Read SEC document
February 16, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	3,021	$0.00	$0.00	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,081 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2014. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document
February 16, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	5,773	$0.00	$0.00	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,060 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2015, and February 1, 2016. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2017 and December 31, 2018, respectively. Read SEC document
February 15, 2017 Filed Feb 22, 2017 02:18 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	315	$59.33	$18,688.95	Disclosure SEC source: 0001127602-17-007551 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,287 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document
February 02, 2017 Filed Feb 7, 2017 02:43 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	104,570	$0.00 Strike: $72.25	$0.00	Disclosure SEC source: 0001127602-17-004209 · form4.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,570 Underlying: Common Stock · 104,570 shares Expires 2027-02-02 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
November 22, 2016 Filed Nov 29, 2016 19:12 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001127602-16-068562 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,306,849 F1 · shares: Gift of shares from family trust to charity. Read SEC document
August 24, 2016 Filed Aug 26, 2016 16:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	2,800	$0.00	$0.00	Disclosure SEC source: 0001127602-16-061215 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,316,849 F1 · shares: Gift of shares from family trust to charity. F2 · balance_after: Shares gifted to family trust on various dates between 2013 and 2016. Read SEC document
February 16, 2016 Filed Feb 19, 2016 00:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	40,716	$91.15	$3,711,263.40	Disclosure SEC source: 0001127602-16-042270 · form4.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,940 Read SEC document
February 16, 2016 Filed Feb 19, 2016 00:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	52,914	$0.00	$0.00	Disclosure SEC source: 0001127602-16-042270 · form4.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,656 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document
February 16, 2016 Filed Feb 19, 2016 00:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	14,326	$0.00	$0.00	Disclosure SEC source: 0001127602-16-042270 · form4.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,742 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2014, and February 1, 2015. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2016, and committee certifications respectively. Read SEC document
February 15, 2016 Filed Feb 19, 2016 00:52 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	248	$76.02	$18,853.95	Disclosure SEC source: 0001127602-16-042270 · form4.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,416 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document
February 01, 2016 Filed Feb 3, 2016 22:44 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Option (right to buy) · Derivative	85,750	$0.00 Strike: $84.05	$0.00	Disclosure SEC source: 0001179110-16-018454 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,750 Underlying: Common Stock · 85,750 shares Expires 2026-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	43,600	$0.00 Strike: $23.76	$0.00	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · derivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 43,600 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	26,400	$0.00 Strike: $19.09	$0.00	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,600 Underlying: Common Stock · 26,400 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	39,569	$102.22	$4,044,782.75	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,936 F3 · price: Sale prices reported for the transactions reported here range from $101.46 to $102.45. Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	30,431	$102.66	$3,123,958.21	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,505 F4 · price: Sale prices reported for the transactions reported here range from $102.46 to $102.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	26,400	$19.09	$503,844.00	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 15, 2015 Filed Dec 17, 2015 20:40 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	43,600	$23.76	$1,035,718.00	Disclosure SEC source: 0001179110-15-016421 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 16, 2015 Filed Nov 18, 2015 17:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	70,000	$0.00 Strike: $23.76	$0.00	Disclosure SEC source: 0001179110-15-015043 · edgar.xml · derivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,400 Underlying: Common Stock · 70,000 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
November 16, 2015 Filed Nov 18, 2015 17:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	5,544	$103.79	$575,395.68	Disclosure SEC source: 0001179110-15-015043 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,168 F5 · price: Sale prices reported for the transactions reported here range from $103.74 to $103.9216. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
November 16, 2015 Filed Nov 18, 2015 17:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	18,981	$103.25	$1,959,881.26	Disclosure SEC source: 0001179110-15-015043 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,712 F4 · price: Sale prices reported for the transactions reported here range from $102.74 to $103.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
November 16, 2015 Filed Nov 18, 2015 17:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	45,475	$102.26	$4,650,141.62	Disclosure SEC source: 0001179110-15-015043 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,693 F3 · price: Sale prices reported for the transactions reported here range from $101.74 to $102.73. Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request Read SEC document
November 16, 2015 Filed Nov 18, 2015 17:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	70,000	$23.76	$1,662,850.00	Disclosure SEC source: 0001179110-15-015043 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 03, 2015 Filed Nov 13, 2015 18:01 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GiftCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001179110-15-014830 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,149,681 F1 · shares: Gift of shares from family trust to charity. Read SEC document
October 15, 2015 Filed Oct 16, 2015 21:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,600	$0.00 Strike: $23.76	$0.00	Disclosure SEC source: 0001179110-15-014072 · edgar.xml · derivative · entry 8 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,400 Underlying: Common Stock · 1,600 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
October 15, 2015 Filed Oct 16, 2015 21:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	68,400	$0.00 Strike: $23.60	$0.00	Disclosure SEC source: 0001179110-15-014072 · edgar.xml · derivative · entry 7 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,400 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
October 15, 2015 Filed Oct 16, 2015 21:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	25,319	$101.18	$2,561,748.57	Disclosure SEC source: 0001179110-15-014072 · edgar.xml · nonDerivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,168 F6 · price: Sale prices reported for the transactions reported here range from $100.64 to $101.625. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.